Accesso libero

Impact of Intraoperative Cell Salvage on Circulating Tumor Cells and Cellular Activity in Patients with Hepatocellular Carcinoma Undergoing Curative Resection: A Prospective Comparative Study

Ke Yue

Ke Yue

  • School of Medicine, Shanghai UniversityShanghai, China
  • Department of Anesthesiology, Gongli Hospital of Shanghai Pudong New AreaShanghai, China
Cerca questo autore su
Sciendo|Google Scholar
Yue, Ke
, 
Lai-wei You

Lai-wei You

Department of Anesthesiology, Gongli Hospital of Shanghai Pudong New AreaShanghai, China
Cerca questo autore su
Sciendo|Google Scholar
You, Lai-wei
, 
Bao-ji Hu

Bao-ji Hu

Department of Anesthesiology, Shanghai Pudong Hospital, Fudan University Pudong Medical CenterShanghai, China
Cerca questo autore su
Sciendo|Google Scholar
Hu, Bao-ji
, 
Yong Cheng

Yong Cheng

Department of Anesthesiology, Gongli Hospital of Shanghai Pudong New AreaShanghai, China
Cerca questo autore su
Sciendo|Google Scholar
Cheng, Yong
, 
Jinhuo Wang

Jinhuo Wang

Department of Anesthesiology, Gongli Hospital of Shanghai Pudong New AreaShanghai, China
Cerca questo autore su
Sciendo|Google Scholar
Wang, Jinhuo
, 
Hao Li

Hao Li

Department of Anesthesiology, Gongli Hospital of Shanghai Pudong New AreaShanghai, China
Cerca questo autore su
Sciendo|Google Scholar
Li, Hao
 e 
Jianrong Guo

Jianrong Guo

Department of Anesthesiology, Gongli Hospital of Shanghai Pudong New AreaShanghai, China
Cerca questo autore su
Sciendo|Google Scholar
Guo, Jianrong
  
23 giu 2025
Impact of Intraoperative Cell Salvage on Circulating Tumor Cells and Cellular Activity in Patients with Hepatocellular Carcinoma Undergoing Curative Resection: A Prospective Comparative Study's Cover Image
INFORMAZIONI SU QUESTO ARTICOLO
Articolo precedente
Articolo Successivo
Cita
Scarica la copertina
Categoria dell'articolo: Original
Pubblicato online: 23 giu 2025
Ricevuto: 18 dic 2024
Accettato: 11 mar 2025
DOI: https://doi.org/10.2478/aite-2025-0015
Parole chiave
© 2025 Ke Yue et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Fig 1.

The apoptosis levels in patients with HCC from different groups were detected at preoperative, intraoperative, and postoperative six points using the ATP cell viability detection assays. ATP, adenosine triphosphate; HCC, hepatocellular carcinoma.
The apoptosis levels in patients with HCC from different groups were detected at preoperative, intraoperative, and postoperative six points using the ATP cell viability detection assays. ATP, adenosine triphosphate; HCC, hepatocellular carcinoma.

Fig 2.

The apoptosis levels in patients with HCC from different groups were detected at preoperative, intraoperative, and postoperative 6 h using flow cytometry assays. HCC, hepatocellular carcinoma.
The apoptosis levels in patients with HCC from different groups were detected at preoperative, intraoperative, and postoperative 6 h using flow cytometry assays. HCC, hepatocellular carcinoma.

Fig 3.

The CTCs in patients with HCC from different groups were detected at preoperative, intraoperative, and postoperative 6 h using an immunomagnetic bead separation combined with flow cytometry assays. CTCs, circulating tumor cell; HCC, hepatocellular carcinoma.
The CTCs in patients with HCC from different groups were detected at preoperative, intraoperative, and postoperative 6 h using an immunomagnetic bead separation combined with flow cytometry assays. CTCs, circulating tumor cell; HCC, hepatocellular carcinoma.

Fig 4.

The expression levels of AFP and GPC3 proteins in patients with HCC from different groups were determined at postoperative 6 h using Western blotting. HCC, hepatocellular carcinoma.
The expression levels of AFP and GPC3 proteins in patients with HCC from different groups were determined at postoperative 6 h using Western blotting. HCC, hepatocellular carcinoma.

Fig 5.

The expression levels of CTNNB1 and TP53 mRNA in patients with HCC from different groups were determined at preoperative and postoperative 6 h using the qRT-PCR. HCC, hepatocellular carcinoma.
The expression levels of CTNNB1 and TP53 mRNA in patients with HCC from different groups were determined at preoperative and postoperative 6 h using the qRT-PCR. HCC, hepatocellular carcinoma.

Fig 6.

The detection of EpCAM in patients with HCC from different groups at preoperative and postoperative 6 h time points, using an immunofluorescence assay. HCC, hepatocellular carcinoma.
The detection of EpCAM in patients with HCC from different groups at preoperative and postoperative 6 h time points, using an immunofluorescence assay. HCC, hepatocellular carcinoma.

Demographic, participants' general data

Variable Experimental group (N = 40) Control group (N = 40) χ2/t P
Gender, male (%) 24 (60%) 22 (55%) 0.331 0.565
Age (years) 65.4 (50.3–73.8) 64.8 (50.4–74.5) 0.319 0.750
BMI (kg/m2) 26.5 (24.1–29.3) 26.9 (23.2–30.5) −0.536 0.594
Child-Pugh classification 0.372 0.543
A 26 (65%) 24 (60%)
B 14 (35%) 16 (40%)
TNM stage 0.492 0.78
I 18 20
II 20 19
III 2 1
IV 0 0
ALT (U/L) 61.3 (41.1–82.3) 61.8 (41.4–81.6) −0.144 0.886
AST (U/L) 56.2 (40.2–76.1) 55.6 (40.6–77.3) 0.233 0.81
Lingua:
Inglese
Frequenza di pubblicazione:
1 volte all'anno
Argomenti della rivista:
Medicina, Scienze medicali di base, Biochimica, Immunologia, Medicina clinica, Medicina clinica, altro, Chimica clinica
Feed RSS della rivista